Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents Article

Full Text via DOI: 10.2337/dc09-2260 PMID: 20332351 Web of Science: 000279304300030
Industry Collaboration International Collaboration

Cited authors

  • Buse, John B.; Sesti, Giorgio; Schmidt, Wolfgang E.; Montanya, Eduard; Chang, Cheng-Tao; Xu, Yizhen; Blonde, Lawrence; Rosenstock, Julio


  • OBJECTIVE - To evaluate efficacy and safety of switching from twice-daily exenatide to once-daily liraglutide or of 40 weeks of continuous liraglutide therapy.; RESEARCH DESIGN AND METHODS - When added to oral antidiabetes drugs in a 26-week randomized trial (Liraglutide Effect and Action in Diabetes [LEAD]-6), liraglutide more effectively improved AlC, fasting plasma glucose, and the homeostasis model of beta-cell function (HOMA-B) than exenatide, with less persistent nausea and hypoglycemia. In this 14-week extension of LEAD-6, patients switched from 10 mu g twice-daily exenatide to 1.8 mg once-daily liraglutide or continued liraglutide.; RESULTS - Switching from exenatide to liraglutide further and significantly reduced AlC (0.32%), fasting plasma glucose (0.9 mmol/l), body weight (0.9 kg), and systolic blood pressure (3.8 mmHg) with minimal minor hypoglycemia (1.30 episodes/patient-year) or nausea (3.2%). Among patients continuing liraglutide, further significant decreases in body weight (0.4 kg) and systolic blood pressure (2.2 mmHg) occurred with 0.74 episodes/patient-year of minor hypoglycemia and 1.5% experiencing nausea.; CONCLUSIONS - Conversion from exenatide to liraglutide is well tolerated and provides additional glycemic control and cardiometabolic benefits.

Publication date

  • 2010

Published in

International Standard Serial Number (ISSN)

  • 0149-5992

Start page

  • 1300

End page

  • 1303


  • 33


  • 6